<\/p>\n
\ud83d\udca1 Raskt svar<\/strong><\/p>\n Etibo<\/strong> is lapatinib 250 mg<\/strong>, en dual HER2\/EGFR tyrosine kinase inhibitor<\/strong> for advanced or metastatic HER2-positive breast cancer<\/strong>. Oral once-daily therapy combined with capecitabine or other regimens, usually after trastuzumab (Herceptin) failure. Significant side effects include diarrhoea, rash, and cardiotoxicity; requires close oncologist supervision and ECG monitoring.<\/p>\n<\/div>\n \ud83d\udce6 Hver ordre er dekket av v\u00e5r Reshipment Assurance Policy<\/strong><\/a> \u2014 hvis pakken din ikke ankommer innen 20 virkedager, sender vi ny.<\/p>\n V\u00e5re generiske legemidler kommer fra WHO-GMP-sertifiserte produsenter og sendes over hele verden i diskret, n\u00f8ytral emballasje \u2014 ingen legemiddelnavn p\u00e5 utsiden av pakken. Kortbetalinger h\u00e5ndteres av en regulert betalingsbehandler (kontoutskrifter viser en regulert kortbetalingsprosessor \u2014 aldri \u201cMedsBase\u201d eller noe legemiddelnavn). Krypto og SEPA bankoverf\u00f8rsel godtas ogs\u00e5. Hver ordre er dekket av v\u00e5r Reshipment Assurance Policy.<\/p>\n Etibo is a branded generic of lapatinib<\/strong> 250 mg, a small-molecule tyrosine kinase inhibitor that targets HER2 (ErbB2)<\/strong> og EGFR (ErbB1)<\/strong>. Lapatinib blocks intracellular signaling downstream of these receptors, halting proliferation of HER2-positive cancer cells. Manufactured by Natco Pharma.<\/p>\n Kritisk:<\/strong> Lapatinib is an oncology drug used only under specialist supervision. It is not a general women’s health product. Use strictly according to oncologist protocol \u2014 typically after trastuzumab resistance develops.<\/p>\n Meget vanlig:<\/strong> diarrhoea (60\u201380%), rash (40\u201360%), nausea, vomiting, fatigue, hand-foot syndrome, palmar-plantar erythrodysesthesia (with capecitabine combo).<\/p>\n Alvorlige:<\/strong> hepatotoxicity<\/strong> (monitor LFTs), cardiotoxicity \/ reduced LVEF<\/strong> (5\u20136%), QT prolongation, interstitial lung disease (rare but serious).<\/p>\n Alvorlige:<\/strong> severe liver injury, heart failure, severe skin reactions (Stevens-Johnson), pulmonary toxicity.<\/p>\n Store at room temperature (15\u201330 \u00b0C), away from moisture. Keep in original packaging. Keep out of reach of children.<\/p>\n Advanced\/metastatic HER2-positive breast cancer, typically after trastuzumab (Herceptin) resistance. Not used for early-stage curative therapy.<\/p>\n Food increases lapatinib absorption 4\u20135\u00d7, making dosing unpredictable. Standard is consistent fasting \u2014 1 hour before or after food \u2014 at a fixed time each day.<\/p>\n Common, often grade 1\u20132; manageable with loperamide and hydration. Grade 3+ diarrhoea may require treatment interruption and dose reduction. Report early.<\/p>\n About 5\u20136% of patients have asymptomatic LVEF drops. ECG + echocardiogram at baseline and every 3 months. Usually reversible on dose adjustment or interruption.<\/p>\n Combination lapatinib + trastuzumab is used in specific protocols. Not routine without oncologist supervision.<\/p>\n Effective contraception required during treatment and for 1 week after (teratogenic). Men should use effective contraception during and 3 months after.<\/p>\n HER2+ breast cancer disproportionately affects women (though rarely men get HER2+ breast cancer). Categorisation reflects the population, not a strict clinical cluster.<\/p>\n For second-line HER2+ metastatic disease (after trastuzumab), lapatinib + capecitabine was standard for years. Newer options (T-DM1\/Kadcyla, T-DXd\/Enhertu, tucatinib) have since largely supplanted it in first-world oncology \u2014 lapatinib remains important where newer agents are unavailable.<\/p>\n \u2695\ufe0f Medisinsk ansvarsfraskrivelse:<\/strong> Informasjonen er veiledende og erstatter ikke medisinsk r\u00e5dgivning. Konsulter en lege f\u00f8r du starter, stopper eller endrer medisiner, spesielt ved kreftbehandling, hormonbehandlinger og reseptbelagte produkter.<\/p>\n<\/div>\n <\/p>\n Andre onkologimedikamenter vi f\u00f8rer sammen med dette produktet:<\/p>\n \u2705 Targets cancer cells Etibo contains Lapatinib.<\/p>","protected":false},"featured_media":58016,"comment_status":"open","ping_status":"open","template":"","meta":[],"product_brand":[],"product_cat":[3595,3141,3223,3502],"product_tag":[4402,4403],"class_list":{"0":"post-58015","1":"product","2":"type-product","3":"status-publish","4":"has-post-thumbnail","6":"product_cat-anti-cancer-medication","7":"product_cat-category-overview","8":"product_cat-chronic-conditions","9":"product_cat-womens-health","10":"product_tag-etibo","11":"product_tag-lapatinib","13":"first","14":"instock","15":"shipping-taxable","16":"purchasable","17":"product-type-variable","18":"has-default-attributes"},"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/nb\/wp-json\/wp\/v2\/product\/58015","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/nb\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/nb\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/nb\/wp-json\/wp\/v2\/comments?post=58015"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/nb\/wp-json\/wp\/v2\/media\/58016"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/nb\/wp-json\/wp\/v2\/media?parent=58015"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/nb\/wp-json\/wp\/v2\/product_brand?post=58015"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/nb\/wp-json\/wp\/v2\/product_cat?post=58015"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/nb\/wp-json\/wp\/v2\/product_tag?post=58015"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}Hvorfor bestille fra MedsBase<\/h3>\n
What Is Etibo?<\/strong><\/h2>\n
Klinisk bruk<\/strong><\/h2>\n
\n
Hvordan ta<\/strong><\/h2>\n
\n
Bivirkninger<\/strong><\/h2>\n
Who Should Not Take Etibo<\/strong><\/h2>\n
\n
Legemiddelinteraksjoner<\/strong><\/h2>\n
\n
Oppbevaring<\/strong><\/h2>\n
Vanlige sp\u00f8rsm\u00e5l<\/h2>\n
When is lapatinib used?<\/h3>\n
Why take on empty stomach?<\/h3>\n
How bad is the diarrhoea?<\/h3>\n
Will lapatinib damage my heart?<\/h3>\n
Can I take lapatinib with trastuzumab?<\/h3>\n
What about fertility?<\/h3>\n
Why is this in the Women's Health category?<\/h3>\n
Is lapatinib still first-line?<\/h3>\n
Relaterte produkter for kvinners helse<\/h3>\n
\n
Relaterte alternativer<\/h3>\n
\n
\n\u2705 Inhibits tumor growth
\n\u2705 Treats breast cancer
\n\u2705 Blocks HER2 receptors
\n\u2705 Forbedrer overlevelsessatser<\/p>\n